Indications for: LUMIGAN

Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.

Clinical Trials:

In a 12-month clinical study of patients with open angle glaucoma or ocular hypertension with an average baseline IOP of 23.5 mmHg, the IOP-lowering effect of Lumigan 0.01% once daily (in the evening) was up to 7.5 mmHg.

Adult Dosage:

≥16yrs: 1 drop in affected eye once daily in the PM.

Children Dosage:

<16yrs: not recommended.

LUMIGAN Warnings/Precautions:

Do not exceed recommended dose. Intraocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.

LUMIGAN Classification:

Prostaglandin analogue.

LUMIGAN Interactions:

Allow at least 5mins between application of other topical ophthalmic agents.

Adverse Reactions:

Conjunctival hyperemia, ocular effects (eg, edema, hemorrhage, irritation, pain, pruritus), hypertrichosis, eyelash growth, visual disturbances, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, keratitis, infection, abnormal liver function tests.


Oxidation, N-deethylation, glucuronidation.

Drug Elimination:

Renal (67%), fecal (25%). Half-life: ~45 minutes.

Generic Drug Availability:


How Supplied:

Soln—2.5mL, 5mL, 7.5mL